Jennifer Lawson
Senior Trial Manager
Jen joined the Diabetes Trials Unit (DTU) in February 2024 as a Senior Trial Manager. She is responsible for supporting all studies within the DTU, but has a particular focus on the Impact of Semaglutide in Amyloid Positivity (ISAP) trial.
She previously worked for 10 years in the Department of Psychiatry, as Senior Trial Manager and National Coordinator for the Deep and Frequent Phenotyping study looking at biomarkers for Alzheimer's disease. Jen provided supervision, line management and support for all trials conducted by the Oxford Dementia and Ageing Research (OXDARE) Trials team.
Prior to this, Jen spent 5 years at Oxford Health NHS Foundation Trust. During this time, she helped establish the NIHR Oxford cognitive health Clinical Research Facility, she set up and coordinated complex, high intensity industry-led clinical trials, and spent 12 months as the Trust's Research Governance Manager.
Jen is also a member and Alternate Vice Chair of the Health Research Authority Research Ethics Committee, Oxford A.
Recent publications
-
Melatonin In Acute Mania Investigation (MIAMI-UK). A randomized controlled trial of add-on melatonin in bipolar disorder.
Journal article
Quested DJ. et al, (2021), Bipolar Disord, 23, 176 - 185
-
Alzheimer's disease research: past approaches and future directions
Journal article
Yehuda MB. et al, (2021), British Journal of Neuroscience Nursing, 17, 34 - 39
-
Neurons from individual early Alzheimer’s disease patients reflect their clinical vulnerability
Preprint
Ng B. et al, (2021)
-
Clinical trials: from problem child to the driving force of medical advancement
Journal article
Delanerolle G. et al, (2020), British Journal of Neuroscience Nursing, 16, 200 - 202
-
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease.
Journal article
Koychev I. et al, (2019), BMJ Open, 9